{"entity":{"type":"insider","cik":"0001597578","url":"/insider/0001597578","json_url":"/insider/0001597578.json","name":"Ruegg Curtis","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":39,"n_filings":24,"first":"2014-09-19","last":"2016-06-15","span_basis":"filed_date"},"name_variants":[{"name":"Ruegg Curtis","source":"filing","n_filings":24,"first_seen":"2014-09-19","last_seen":"2016-06-15"}],"transactions":[{"id":2827079,"accession":"0001209191-16-128066","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-16-128066","line_url":"/filing/0001209191-16-128066#line-2","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001597578","owner_name":"Ruegg Curtis","owner_display_name":"Ruegg Curtis","owner_url":"/insider/0001597578","role":"Officer (EVP, Technical Operations)","role_mark":"O","role_mark_label":"Officer (EVP, Technical Operations)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Technical Operations","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1000.0,"shares_display":"1,000","price_per_share":18.25,"price_display":"18.25","price_state":"stated","total_value":18250.0,"total_display":"18,250.00","total_whole":"18,250","shares_owned_after":23944.0,"shares_owned_after_display":"23,944","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-06-13","filed_date":"2016-06-15","scope":"insider"},{"id":2469241,"accession":"0001209191-16-119301","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-16-119301","line_url":"/filing/0001209191-16-119301#line-2","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001597578","owner_name":"Ruegg Curtis","owner_display_name":"Ruegg Curtis","owner_url":"/insider/0001597578","role":"Officer (EVP, Technical Operations)","role_mark":"O","role_mark_label":"Officer (EVP, Technical Operations)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Technical Operations","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1000.0,"shares_display":"1,000","price_per_share":16.18,"price_display":"16.18","price_state":"stated","total_value":16180.0,"total_display":"16,180.00","total_whole":"16,180","shares_owned_after":25264.0,"shares_owned_after_display":"25,264","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-05-09","filed_date":"2016-05-11","scope":"insider"},{"id":3254897,"accession":"0001209191-16-114143","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-16-114143","line_url":"/filing/0001209191-16-114143#line-2","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001597578","owner_name":"Ruegg Curtis","owner_display_name":"Ruegg Curtis","owner_url":"/insider/0001597578","role":"Officer (EVP, Technical Operations)","role_mark":"O","role_mark_label":"Officer (EVP, Technical Operations)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Technical Operations","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1000.0,"shares_display":"1,000","price_per_share":19.11,"price_display":"19.11","price_state":"stated","total_value":19110.0,"total_display":"19,110.00","total_whole":"19,110","shares_owned_after":25264.0,"shares_owned_after_display":"25,264","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-04-11","filed_date":"2016-04-13","scope":"insider"},{"id":2508034,"accession":"0001209191-16-107456","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-16-107456","line_url":"/filing/0001209191-16-107456#line-2","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001597578","owner_name":"Ruegg Curtis","owner_display_name":"Ruegg Curtis","owner_url":"/insider/0001597578","role":"Officer (EVP, Technical Operations)","role_mark":"O","role_mark_label":"Officer (EVP, Technical Operations)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Technical Operations","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1000.0,"shares_display":"1,000","price_per_share":20.43,"price_display":"20.43","price_state":"stated","total_value":20430.0,"total_display":"20,430.00","total_whole":"20,430","shares_owned_after":25264.0,"shares_owned_after_display":"25,264","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-03-07","filed_date":"2016-03-09","scope":"insider"},{"id":3077980,"accession":"0001209191-16-097462","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-16-097462","line_url":"/filing/0001209191-16-097462#line-2","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001597578","owner_name":"Ruegg Curtis","owner_display_name":"Ruegg Curtis","owner_url":"/insider/0001597578","role":"Officer (EVP, Technical Operations)","role_mark":"O","role_mark_label":"Officer (EVP, Technical Operations)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Technical Operations","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1000.0,"shares_display":"1,000","price_per_share":18.14,"price_display":"18.14","price_state":"stated","total_value":18140.0,"total_display":"18,140.00","total_whole":"18,140","shares_owned_after":17264.0,"shares_owned_after_display":"17,264","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-02-08","filed_date":"2016-02-10","scope":"insider"},{"id":2816879,"accession":"0001209191-16-090637","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-16-090637","line_url":"/filing/0001209191-16-090637#line-2","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001597578","owner_name":"Ruegg Curtis","owner_display_name":"Ruegg Curtis","owner_url":"/insider/0001597578","role":"Officer (EVP, Technical Operations)","role_mark":"O","role_mark_label":"Officer (EVP, Technical Operations)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Technical Operations","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2000.0,"shares_display":"2,000","price_per_share":33.06,"price_display":"33.06","price_state":"stated","total_value":66120.0,"total_display":"66,120.00","total_whole":"66,120","shares_owned_after":18027.0,"shares_owned_after_display":"18,027","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-01-06","filed_date":"2016-01-08","scope":"insider"},{"id":8751499,"accession":"0001209191-15-066998","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0001209191-15-066998","line_url":"/filing/0001209191-15-066998","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001597578","owner_name":"Ruegg Curtis","owner_display_name":"Ruegg Curtis","owner_url":"/insider/0001597578","role":"Officer (EVP, Technical Operations)","role_mark":"O","role_mark_label":"Officer (EVP, Technical Operations)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Technical Operations","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3000.0,"shares_display":"3,000","price_per_share":30.33004,"price_display":"30.33","price_state":"stated","total_value":90990.12,"total_display":"90,990.12","total_whole":"90,990","shares_owned_after":20027.0,"shares_owned_after_display":"20,027","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-08-17","filed_date":"2015-08-19","scope":"insider","n_lines":6},{"id":8648501,"accession":"0001209191-15-061951","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-15-061951","line_url":"/filing/0001209191-15-061951#line-3","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001597578","owner_name":"Ruegg Curtis","owner_display_name":"Ruegg Curtis","owner_url":"/insider/0001597578","role":"Officer (EVP, Technical Operations)","role_mark":"O","role_mark_label":"Officer (EVP, Technical Operations)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Technical Operations","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3000.0,"shares_display":"3,000","price_per_share":31.03,"price_display":"31.03","price_state":"stated","total_value":93090.0,"total_display":"93,090.00","total_whole":"93,090","shares_owned_after":18027.0,"shares_owned_after_display":"18,027","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-07-17","filed_date":"2015-07-21","scope":"insider"},{"id":8070642,"accession":"0001209191-15-055189","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-15-055189","line_url":"/filing/0001209191-15-055189#line-2","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001597578","owner_name":"Ruegg Curtis","owner_display_name":"Ruegg Curtis","owner_url":"/insider/0001597578","role":"Officer (EVP, Technical Operations)","role_mark":"O","role_mark_label":"Officer (EVP, Technical Operations)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Technical Operations","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3000.0,"shares_display":"3,000","price_per_share":33.531,"price_display":"33.53","price_state":"stated","total_value":100593.0,"total_display":"100,593.00","total_whole":"100,593","shares_owned_after":18027.0,"shares_owned_after_display":"18,027","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-06-17","filed_date":"2015-06-19","scope":"insider"},{"id":8903604,"accession":"0001209191-15-050802","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-15-050802","line_url":"/filing/0001209191-15-050802#line-2","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001597578","owner_name":"Ruegg Curtis","owner_display_name":"Ruegg Curtis","owner_url":"/insider/0001597578","role":"Officer (EVP, Technical Operations)","role_mark":"O","role_mark_label":"Officer (EVP, Technical Operations)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Technical Operations","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":500.0,"shares_display":"500","price_per_share":30.0,"price_display":"30.00","price_state":"stated","total_value":15000.0,"total_display":"15,000.00","total_whole":"15,000","shares_owned_after":18027.0,"shares_owned_after_display":"18,027","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-06-03","filed_date":"2015-06-05","scope":"insider"},{"id":8812175,"accession":"0001209191-15-044673","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0001209191-15-044673","line_url":"/filing/0001209191-15-044673","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001597578","owner_name":"Ruegg Curtis","owner_display_name":"Ruegg Curtis","owner_url":"/insider/0001597578","role":"Officer (EVP, Technical Operations)","role_mark":"O","role_mark_label":"Officer (EVP, Technical Operations)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Technical Operations","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2500.0,"shares_display":"2,500","price_per_share":26.6988,"price_display":"26.70","price_state":"stated","total_value":66747.0,"total_display":"66,747.00","total_whole":"66,747","shares_owned_after":19337.0,"shares_owned_after_display":"19,337","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-05-18","filed_date":"2015-05-19","scope":"insider","n_lines":4},{"id":8812170,"accession":"0001209191-15-044673","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-15-044673","line_url":"/filing/0001209191-15-044673#line-2","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001597578","owner_name":"Ruegg Curtis","owner_display_name":"Ruegg Curtis","owner_url":"/insider/0001597578","role":"Officer (EVP, Technical Operations)","role_mark":"O","role_mark_label":"Officer (EVP, Technical Operations)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Technical Operations","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":500.0,"shares_display":"500","price_per_share":25.0,"price_display":"25.00","price_state":"stated","total_value":12500.0,"total_display":"12,500.00","total_whole":"12,500","shares_owned_after":19337.0,"shares_owned_after_display":"19,337","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-05-15","filed_date":"2015-05-19","scope":"insider"},{"id":8802547,"accession":"0001209191-15-035361","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-15-035361","line_url":"/filing/0001209191-15-035361","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001597578","owner_name":"Ruegg Curtis","owner_display_name":"Ruegg Curtis","owner_url":"/insider/0001597578","role":"Officer (EVP, Technical Operations)","role_mark":"O","role_mark_label":"Officer (EVP, Technical Operations)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Technical Operations","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2000.0,"shares_display":"2,000","price_per_share":22.23325,"price_display":"22.23","price_state":"stated","total_value":44466.5,"total_display":"44,466.50","total_whole":"44,467","shares_owned_after":19337.0,"shares_owned_after_display":"19,337","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-04-17","filed_date":"2015-04-21","scope":"insider","n_lines":2},{"id":8598453,"accession":"0001209191-15-028590","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-15-028590","line_url":"/filing/0001209191-15-028590#line-2","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001597578","owner_name":"Ruegg Curtis","owner_display_name":"Ruegg Curtis","owner_url":"/insider/0001597578","role":"Officer (EVP, Technical Operations)","role_mark":"O","role_mark_label":"Officer (EVP, Technical Operations)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Technical Operations","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":500.0,"shares_display":"500","price_per_share":20.0,"price_display":"20.00","price_state":"stated","total_value":10000.0,"total_display":"10,000.00","total_whole":"10,000","shares_owned_after":19337.0,"shares_owned_after_display":"19,337","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-03-19","filed_date":"2015-03-23","scope":"insider"},{"id":8811818,"accession":"0001209191-15-027995","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-15-027995","line_url":"/filing/0001209191-15-027995#line-2","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001597578","owner_name":"Ruegg Curtis","owner_display_name":"Ruegg Curtis","owner_url":"/insider/0001597578","role":"Officer (EVP, Technical Operations)","role_mark":"O","role_mark_label":"Officer (EVP, Technical Operations)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Technical Operations","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1500.0,"shares_display":"1,500","price_per_share":18.61,"price_display":"18.61","price_state":"stated","total_value":27915.0,"total_display":"27,915.00","total_whole":"27,915","shares_owned_after":19337.0,"shares_owned_after_display":"19,337","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-03-17","filed_date":"2015-03-19","scope":"insider"},{"id":8247792,"accession":"0001209191-15-025334","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-15-025334","line_url":"/filing/0001209191-15-025334#line-2","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001597578","owner_name":"Ruegg Curtis","owner_display_name":"Ruegg Curtis","owner_url":"/insider/0001597578","role":"Officer (EVP, Technical Operations)","role_mark":"O","role_mark_label":"Officer (EVP, Technical Operations)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Technical Operations","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":500.0,"shares_display":"500","price_per_share":18.0,"price_display":"18.00","price_state":"stated","total_value":9000.0,"total_display":"9,000.00","total_whole":"9,000","shares_owned_after":19337.0,"shares_owned_after_display":"19,337","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-03-09","filed_date":"2015-03-11","scope":"insider"},{"id":8802054,"accession":"0001209191-15-015645","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-15-015645","line_url":"/filing/0001209191-15-015645","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001597578","owner_name":"Ruegg Curtis","owner_display_name":"Ruegg Curtis","owner_url":"/insider/0001597578","role":"Officer (EVP, Technical Operations)","role_mark":"O","role_mark_label":"Officer (EVP, Technical Operations)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Technical Operations","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1000.0,"shares_display":"1,000","price_per_share":16.8,"price_display":"16.80","price_state":"stated","total_value":16800.0,"total_display":"16,800.00","total_whole":"16,800","shares_owned_after":19337.0,"shares_owned_after_display":"19,337","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-02-17","filed_date":"2015-02-18","scope":"insider","n_lines":2},{"id":8811207,"accession":"0001209191-15-005965","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-15-005965","line_url":"/filing/0001209191-15-005965#line-2","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001597578","owner_name":"Ruegg Curtis","owner_display_name":"Ruegg Curtis","owner_url":"/insider/0001597578","role":"Officer (EVP R&D and Tech Operations)","role_mark":"O","role_mark_label":"Officer (EVP R&D and Tech Operations)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP R&D and Tech Operations","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1000.0,"shares_display":"1,000","price_per_share":17.25,"price_display":"17.25","price_state":"stated","total_value":17250.0,"total_display":"17,250.00","total_whole":"17,250","shares_owned_after":14106.0,"shares_owned_after_display":"14,106","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-01-20","filed_date":"2015-01-22","scope":"insider"},{"id":8824432,"accession":"0001209191-15-003990","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-15-003990","line_url":"/filing/0001209191-15-003990#line-3","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001597578","owner_name":"Ruegg Curtis","owner_display_name":"Ruegg Curtis","owner_url":"/insider/0001597578","role":"Officer (EVP R&D and Tech Operations)","role_mark":"O","role_mark_label":"Officer (EVP R&D and Tech Operations)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP R&D and Tech Operations","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":500.0,"shares_display":"500","price_per_share":18.0,"price_display":"18.00","price_state":"stated","total_value":9000.0,"total_display":"9,000.00","total_whole":"9,000","shares_owned_after":14106.0,"shares_owned_after_display":"14,106","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-01-09","filed_date":"2015-01-13","scope":"insider"},{"id":6532738,"accession":"0001209191-14-077080","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-14-077080","line_url":"/filing/0001209191-14-077080#line-2","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001597578","owner_name":"Ruegg Curtis","owner_display_name":"Ruegg Curtis","owner_url":"/insider/0001597578","role":"Officer (EVP R&D and Tech Operations)","role_mark":"O","role_mark_label":"Officer (EVP R&D and Tech Operations)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP R&D and Tech Operations","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1000.0,"shares_display":"1,000","price_per_share":16.45,"price_display":"16.45","price_state":"stated","total_value":16450.0,"total_display":"16,450.00","total_whole":"16,450","shares_owned_after":14106.0,"shares_owned_after_display":"14,106","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-12-17","filed_date":"2014-12-19","scope":"insider"},{"id":7020488,"accession":"0001209191-14-074650","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-14-074650","line_url":"/filing/0001209191-14-074650#line-2","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001597578","owner_name":"Ruegg Curtis","owner_display_name":"Ruegg Curtis","owner_url":"/insider/0001597578","role":"Officer (EVP R&D and Tech Operations)","role_mark":"O","role_mark_label":"Officer (EVP R&D and Tech Operations)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP R&D and Tech Operations","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":500.0,"shares_display":"500","price_per_share":18.0,"price_display":"18.00","price_state":"stated","total_value":9000.0,"total_display":"9,000.00","total_whole":"9,000","shares_owned_after":14106.0,"shares_owned_after_display":"14,106","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-12-09","filed_date":"2014-12-11","scope":"insider"},{"id":7075807,"accession":"0001209191-14-070491","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-14-070491","line_url":"/filing/0001209191-14-070491#line-2","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001597578","owner_name":"Ruegg Curtis","owner_display_name":"Ruegg Curtis","owner_url":"/insider/0001597578","role":"Officer (EVP R&D and Tech Operations)","role_mark":"O","role_mark_label":"Officer (EVP R&D and Tech Operations)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP R&D and Tech Operations","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1000.0,"shares_display":"1,000","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":16000.0,"total_display":"16,000.00","total_whole":"16,000","shares_owned_after":14106.0,"shares_owned_after_display":"14,106","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-11-18","filed_date":"2014-11-20","scope":"insider"},{"id":6679884,"accession":"0001209191-14-065460","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-14-065460","line_url":"/filing/0001209191-14-065460#line-2","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001597578","owner_name":"Ruegg Curtis","owner_display_name":"Ruegg Curtis","owner_url":"/insider/0001597578","role":"Officer (EVP R&D and Tech Operations)","role_mark":"O","role_mark_label":"Officer (EVP R&D and Tech Operations)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP R&D and Tech Operations","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":500.0,"shares_display":"500","price_per_share":20.0,"price_display":"20.00","price_state":"stated","total_value":10000.0,"total_display":"10,000.00","total_whole":"10,000","shares_owned_after":13268.0,"shares_owned_after_display":"13,268","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-10-28","filed_date":"2014-10-30","scope":"insider"},{"id":6388315,"accession":"0001209191-14-064188","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-14-064188","line_url":"/filing/0001209191-14-064188","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001597578","owner_name":"Ruegg Curtis","owner_display_name":"Ruegg Curtis","owner_url":"/insider/0001597578","role":"Officer (EVP R&D and Tech Operations)","role_mark":"O","role_mark_label":"Officer (EVP R&D and Tech Operations)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP R&D and Tech Operations","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1500.0,"shares_display":"1,500","price_per_share":18.559433333333335,"price_display":"18.56","price_state":"stated","total_value":27839.15,"total_display":"27,839.15","total_whole":"27,839","shares_owned_after":13768.0,"shares_owned_after_display":"13,768","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-10-17","filed_date":"2014-10-21","scope":"insider","n_lines":2},{"id":6531308,"accession":"0001209191-14-058913","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001209191-14-058913","line_url":"/filing/0001209191-14-058913","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001597578","owner_name":"Ruegg Curtis","owner_display_name":"Ruegg Curtis","owner_url":"/insider/0001597578","role":"Officer (EVP R&D and Tech Operations)","role_mark":"O","role_mark_label":"Officer (EVP R&D and Tech Operations)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP R&D and Tech Operations","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2000.0,"shares_display":"2,000","price_per_share":20.5490004,"price_display":"20.55","price_state":"stated","total_value":41098.0008,"total_display":"41,098.00","total_whole":"41,098","shares_owned_after":13268.0,"shares_owned_after_display":"13,268","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-09-17","filed_date":"2014-09-19","scope":"insider","n_lines":4}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":39,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":39,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":39},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001479290","name":"Revance Therapeutics, Inc.","url":"/issuer/0001479290","role":"Officer (EVP, Technical Operations)","n_filings":24,"first_seen":"2014-09-19","last_seen":"2016-06-15"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001597578","retrieved_at":"2026-08-27T23:20:41+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-26","last_ingest":"2026-08-27T05:24:39.644631+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}